- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Monte Rosa Therapeutics Inc (GLUE)
"Monte Rosa Therapeutics Inc stock price live, this page displays NASDAQ GLUE stock exchange data. View the GLUE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Monte Rosa Therapeutics Inc real time stock price chart below.
What Is the Monte Rosa Therapeutics Inc Stock Price Today?
The Monte Rosa Therapeutics Inc stock price today is 4.46.
What Is the Stock Symbol for Monte Rosa Therapeutics Inc?
The stock symbol for Monte Rosa Therapeutics Inc is ""GLUE.""
What Stock Exchange Does Monte Rosa Therapeutics Inc Trade On?
Monte Rosa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Monte Rosa Therapeutics Inc a Good Stock to Buy?
Determining whether Monte Rosa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLUE quote. (ISIN: US61225M1027)"
What Is the Monte Rosa Therapeutics Inc Stock Price Today?
The Monte Rosa Therapeutics Inc stock price today is 4.46.
What Is the Stock Symbol for Monte Rosa Therapeutics Inc?
The stock symbol for Monte Rosa Therapeutics Inc is ""GLUE.""
What Stock Exchange Does Monte Rosa Therapeutics Inc Trade On?
Monte Rosa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Monte Rosa Therapeutics Inc a Good Stock to Buy?
Determining whether Monte Rosa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLUE quote. (ISIN: US61225M1027)"
NASDAQ
Currency in USD
4.46
-0.09(-1.98%)
Closed·
After Hours
4.46-0.01(-0.22%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.38
4.70
52 wk Range
3.21
12.40
GLUE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.384.70
52 wk Range
3.2112.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GLUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
16.13
Upside
+261.55%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Monte Rosa Therapeutics Inc Company Profile
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics Inc Earnings Call Summary for Q4/2024
- Monte Rosa projects strong cash runway into 2028, maintaining robust liquidity with a current ratio of 6.03
- Phase I results for VAV1 program show significant protein degradation and cytokine inhibition
- Strategic collaboration with Novartis announced; expansion in prostate cancer studies planned
- Revenue of $60.64M beats forecast of $51.19M by 18.4%; EPS not disclosed
- IND submission for MRT-8102 program planned for H1 2024; prostate cancer study data expected in H2 2024
Last Updated: 2025/03/20, 15:22
Read Full TranscriptCompare GLUE to Peers and Sector
Metrics to compare | GLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −1.1x | −0.5x | |
PEG Ratio | −0.06 | 0.01 | 0.00 | |
Price/Book | 1.2x | 1.9x | 2.6x | |
Price / LTM Sales | 3.6x | 23.4x | 2.9x | |
Upside (Analyst Target) | 261.1% | 42.3% | 60.8% | |
Fair Value Upside | Unlock | 15.6% | 10.8% | Unlock |
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 16.13
(+261.55% Upside)
Earnings
Latest Release
Mar 20, 2025
EPS / Forecast
-0.3581 / 0.18
Revenue / Forecast
60.64M / 51.19M
FAQ
What Is the Monte Rosa Therapeutics (GLUE) Stock Price Today?
The Monte Rosa Therapeutics stock price today is 4.46
What Stock Exchange Does Monte Rosa Therapeutics Trade On?
Monte Rosa Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Monte Rosa Therapeutics?
The stock symbol for Monte Rosa Therapeutics is "GLUE."
What Is the Monte Rosa Therapeutics Market Cap?
As of today, Monte Rosa Therapeutics market cap is 274.33M.
What is Monte Rosa Therapeutics Earnings Per Share?
The Monte Rosa Therapeutics EPS is -0.98.
What Is the Next Monte Rosa Therapeutics Earnings Date?
Monte Rosa Therapeutics will release its next earnings report on 07 May 2025.
From a Technical Analysis Perspective, Is GLUE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.